Clinical Trial Update: Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update reports on the combination of oblimersen (Genasense) with cytarabine and daunorubicin in older adults with acute myeloid leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Inv
• Untreated Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Genasense (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Status: COMPLETED